• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

    11/12/24 9:30:20 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLDB alert in real time by email
    SC 13G/A 1 p24-3027sc13ga.htm SOLID BIOSCIENCES INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Solid Biosciences Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    83422E204

    (CUSIP Number)
     

    September 30, 2024**

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** The original Schedule 13G filed with the Securities and Exchange Commission with respect to the shares of Common Stock held by the Reporting Persons (as defined in Item 2(a) hereof) prior to the date hereof was filed by Adage Capital Partners GP, L.L.C. (CIK 0001165408), which is no longer a Reporting Person with respect to the shares of Common Stock held by the Reporting Persons.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 83422E20413G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,754,159

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,754,159

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,754,159

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.55%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 83422E20413G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,754,159

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,754,159

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,754,159

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.55%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 83422E20413G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,754,159

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,754,159

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,754,159

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.55%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 83422E20413G/APage 5 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Solid Biosciences Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”), with respect to the shares of Common Stock directly held by ACP;
       
      (ii) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and
       
      (iii) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACM is a limited partnership organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      83422E204

     

     

    CUSIP No. 83422E20413G/APage 6 of 8 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.                                                             

     

    Item 4. OWNERSHIP
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G/A is calculated based upon 38,595,237 shares of Common Stock outstanding as of August 9, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 13, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2(a).

     

     

    CUSIP No. 83422E20413G/APage 7 of 8 Pages

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 83422E20413G/APage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       

    /s/ Robert Atchinson

     
    Name:  Robert Atchinson  
    Title: Managing Member  
       

    /s/ Robert Atchinson

     
    ROBERT ATCHINSON, individually  
       

    /s/ Phillip Gross

     
    PHILLIP GROSS, individually  

     

    Get the next $SLDB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SLDB

    DatePrice TargetRatingAnalyst
    6/26/2025$14.00Buy
    Citigroup
    1/8/2025$16.00Buy
    Truist
    12/13/2024$16.00Outperform
    Wedbush
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    5/31/2024$20.00Overweight
    Piper Sandler
    3/28/2024$40.00Outperform
    William Blair
    More analyst ratings

    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Ian F converted options into 4,573 shares, increasing direct ownership by 4% to 122,119 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      7/8/25 8:04:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Keresty Georgia

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      6/18/25 4:05:04 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Stone Adam Leo

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      6/13/25 5:06:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 4:17:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

      - SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - - Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need - CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced approval of its Investigational

      7/8/25 4:05:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units ("RSUs") to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducem

      7/1/25 4:05:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units ("RSUs") to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement

      6/3/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    SEC Filings

    See more
    • Solid Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Solid Biosciences Inc. (0001707502) (Filer)

      6/13/25 4:21:19 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Solid Biosciences Inc.

      S-8 - Solid Biosciences Inc. (0001707502) (Filer)

      6/13/25 4:02:48 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Solid Biosciences Inc.

      EFFECT - Solid Biosciences Inc. (0001707502) (Filer)

      5/28/25 12:15:12 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Solid Biosciences with a new price target

      Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $14.00

      6/26/25 8:11:57 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Truist initiated coverage on Solid Biosciences with a new price target

      Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

      1/8/25 8:30:04 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Solid Biosciences with a new price target

      Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00

      12/13/24 8:18:51 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

      SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 7:59:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Solid Biosciences Inc.

      SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 12:02:53 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

      SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 8:56:19 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Solid Biosciences Provides Third Quarter Business Update and Financial Results

      – IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme

      11/8/23 4:17:49 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

      - Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc

      10/2/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Financials

    Live finance-specific insights

    See more
    • Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

      — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants

      2/18/25 6:45:43 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

      - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a

      1/7/25 4:15:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

      - Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ

      3/23/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care